NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, Forecast & News

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Shares of Arena Pharmaceuticals reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.32) by $0.14. The biopharmaceutical company earned $1.35 million during the quarter, compared to analyst estimates of $2.06 million. Arena Pharmaceuticals had a return on equity of 42.34% and a net margin of 68.29%. The business's revenue for the quarter was down 62.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.70) earnings per share. View Arena Pharmaceuticals' Earnings History.

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Arena Pharmaceuticals.

Arena Pharmaceuticals will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 equities research analysts have issued twelve-month target prices for Arena Pharmaceuticals' shares. Their forecasts range from $51.00 to $83.00. On average, they expect Arena Pharmaceuticals' share price to reach $66.20 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arena Pharmaceuticals.

News stories about ARNA stock have been trending neutral on Tuesday, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a news impact score of 0.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Arena Pharmaceuticals.

Some companies that are related to Arena Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Canopy Growth (CGC), Cytokinetics (CYTK), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Cara Therapeutics (CARA).

Arena Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (3.68%), FMR LLC (2.41%), Alliancebernstein L.P. (2.20%), Partner Fund Management L.P. (2.14%), Eagle Asset Management Inc. (1.88%) and Alyeska Investment Group L.P. (1.53%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Institutional Ownership Trends for Arena Pharmaceuticals.

ARNA stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., State Street Corp, Pictet Asset Management Ltd., Rafferty Asset Management LLC, UBS Group AG, Chartwell Investment Partners LLC, Russell Investments Group Ltd. and First Trust Advisors LP. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Insider Buying and Selling for Arena Pharmaceuticals.

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Man Group plc, Point72 Asset Management L.P., Alyeska Investment Group L.P., GW&K Investment Management LLC, Marshall Wace North America L.P., Rhenman & Partners Asset Management AB and Barclays PLC. View Insider Buying and Selling for Arena Pharmaceuticals.

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARNA stock can currently be purchased for approximately $49.28.

Arena Pharmaceuticals has a market capitalization of $2.47 billion and generates $17.97 million in revenue each year. The biopharmaceutical company earns $-29,400,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.View Additional Information About Arena Pharmaceuticals.

The official website for Arena Pharmaceuticals is http://www.arenapharm.com/.

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]